Camlin Fine Sciences Share Price
12 Aug, 2026 3:59 PM (IST)
Camlin Fine Sciences Performance
- Today's Low
- ₹107
- Today's High
- ₹120
- 52 Week Low
- ₹96
- 52 Week High
- ₹235
- Open Price₹119
- Previous Close₹126
- Volume6,401,588
- 50 DMA₹127.00
- 100 DMA₹130.60
- 200 DMA₹142.30
Camlin Fine Sciences Chart
Investment Returns
- Over 1 Month -16.02%
- Over 3 Month -14.64%
- Over 6 Month -37.42%
- Over 1 Year -52.28%
Smart Investing Starts Here Start SIP with Camlin Fine Sciences for Steady Growth!
Camlin Fine Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 352.5
- PEG Ratio
- 3.4
- Market Cap Cr
- 2,073
- P/B Ratio
- 2
- Average True Range
- 5.9
- EPS
- 0.3
- Dividend Yield
- 0
- MACD Signal
- -2
- RSI
- 28.18
- MFI
- 31.55
Latest Stock News Updates
Newspaper Publication - Unaudited Financial Results for the quarter ended June 30, 2026.
- BSE India
- 8 hours 46 minutes ago
Investor Call Recording Q1 FY27
- BSE India
- 1 day 4 hours ago
<h3><span style="font-size:16px;"><strong>Specialty Chemicals company Camlin Fine Sciences announced Q1FY27 results</strong></span></h3> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Revenue from Operations:</strong> The consolidated revenue from operations for Q1FY27 stood at Rs 5,198.79 million, representing a growth of 27.51% YoY from Rs 4,077.21 million in Q1FY26 and an increase of 22.38% QoQ from Rs 4,248.11 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Total Income:</strong> Total income for the quarter reached Rs 5,212.19 million in Q1FY27, compared to Rs 4,143.48 million in Q1FY26 and Rs 4,487.23 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Net Profit/(Loss):</strong> The group reported a consolidated net loss for the period of Rs 336.22 million in Q1FY27, as against a net profit of Rs 862.77 million in Q4FY26 and a net loss of Rs 106.81 million in Q1FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Total Comprehensive Income:</strong> Total comprehensive loss for Q1FY27 was Rs 163.62 million, compared to a comprehensive income of Rs 12.48 million in Q1FY26 and Rs 743.85 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Earnings Per Share (EPS):</strong> The basic and diluted EPS for Q1FY27 stood at negative Rs 1.65.</li> </ul> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Revenue from Operations:</strong> Standalone revenue from operations for Q1FY27 was Rs 2,224.86 million, up 16.22% YoY from Rs 1,914.38 million in Q1FY26 and up 21.23% QoQ from Rs 1,835.17 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Total Income:</strong> Total standalone income stood at Rs 2,238.88 million in Q1FY27, compared to Rs 1,951.27 million in Q1FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Net Profit/(Loss):</strong> The company recorded a standalone net loss of Rs 123.12 million in Q1FY27, compared to a loss of Rs 106.81 million in Q1FY26 and a loss of Rs 56.49 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Total Comprehensive Income:</strong> Standalone total comprehensive loss for the quarter was Rs 86.28 million in Q1FY27, compared to a loss of Rs 104.56 million in Q1FY26 and Rs 66.42 million in Q4FY26.</li> </ul> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Segment Performance:</strong> The group transitioned to reporting under three business segments starting from Q1FY27: <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Specialty Ingredients:</strong> Segment revenue reached Rs 4,013.17 million with segment results of Rs 254.66 million.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Aroma:</strong> Segment revenue stood at Rs 774.07 million, with a segment loss of Rs 33.81 million.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Performance Chemicals & Others:</strong> Segment revenue recorded at Rs 1,748.90 million, with a segment loss of Rs 44.41 million.</li> </ul> </li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Exceptional Items:</strong> The consolidated results include an exceptional expense of Rs 111.10 million. This primarily includes Rs 108.8 million representing the shortfall from an insurance claim settlement related to a fire incident on February 7, 2026, at a blending unit of CFS Do Brasil, a wholly-owned subsidiary.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Vinpai S.A. Acquisition:</strong> Following an open offer that closed on July 6, 2026, the company increased its shareholding in Vinpai S.A. to 95.41% by acquiring an additional 501,842 equity shares for Rs 194.63 million.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Operational Update (Dahej Unit):</strong> A fire incident occurred at the Diphenol manufacturing unit at Dahej on May 23, 2026. Management noted that the loss of machinery, inventories, and related expenses, totaling Rs 67.03 million, is entirely covered by insurance, and no residual loss is expected.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Liquidation of Subsidiary:</strong> The liquidation process for CFS Europe SpA (an erstwhile wholly-owned subsidiary) is ongoing. Assets and liabilities were de-recognized effective March 17, 2026, and legal expenses of Rs 2.50 million were incurred during the current quarter.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Employee Stock Options:</strong> During Q1FY27, no employee stock options were issued or allotted. A total of 80,000 options lapsed under ESOP 2021 and were returned to the option pool.</li> </ul> <p><a class="lb" href="/get-document/post/pdf/5780196/" target="_blank">Result PDF</a></p>
- Trendlyne
- 1 day 5 hours ago
Camlin Fine Sciences Financials
Camlin Fine Sciences Technicals
EMA & SMA
- Bearish Moving Average 16
- Bullish Moving Average 0
- 20 Day
- ₹125.30
- 50 Day
- ₹127.00
- 100 Day
- ₹130.60
- 200 Day
- ₹142.30
Resistance and Support
- R3 129.00
- R2 124.40
- R1 116.20
- S1 103.30
- S2 98.80
- S3 90.50
Camlin Fine Sciences Corporate Actions - Bonus, Splits, Dividends
About Camlin Fine Sciences
Camlin Fine Sciences engaged in research, development, manufacturing and marketing of speciality chemicals, ingredients and additive blends. View More- NSE Symbol
- CAMLINFINE
- BSE Symbol
- 532834
- ISIN
- INE052I01032
Similar Stocks to Camlin Fine Sciences
Popular Stocks
Camlin Fine Sciences FAQs
Camlin Fine Sciences share price is ₹107 As on 12 August, 2026 | 23:20
The Market Cap of Camlin Fine Sciences is ₹2073.4 Cr As on 12 August, 2026 | 23:20
The P/E ratio of Camlin Fine Sciences is 352.5 As on 12 August, 2026 | 23:20
The PB ratio of Camlin Fine Sciences is 2 As on 12 August, 2026 | 23:20
The 52 week High & Low of Camlin Fine Sciences is ₹235/₹96.2 respectively As on 12 August, 2026 | 23:20
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.